[24 Jan 2017] Johan Almgren from the masters program Nuclear Science and Technology at Chalmers University of Technology has started his one semester (30 credits) diploma work within the TAT group this January. He will work on polylysine based Pretargeted Radioimmunoteharpy (PRIT).
[13 May 2016] Former PhD-student of the TAT-group, Sofia Frost, is one of the recipients of the Alavi-Mandell Award for JNM articles published in 2015 for her paper "¿-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation". The study was accomplished during her postdoc at Fred Hutchinson Cancer Research Center in collaboration with the TAT-group.
[2 May 2016] Yana Dekempeneer from the In Vivo Cellular and Molecular Imaging (ICMI) Lab of the Vrije Universiteit Brussel (VUB) will be visiting the TAT group for two months this spring to work with targeted alpha therapy using astatinated nanobodies. She has just recently published an overview article on the subject ¿Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle¿.
[25 Mar 2016] Anna Gustafsson-Lutz, PhD student in the TAT group under supervisor Sture Lindegren, successfully defended her thesis "Development of targeted a therapy with Bi-213 and At-211 for the treatment of disseminated cancer - Synthesis and evaluation of pretargeting components and radioimmunoconjugates" on the 23rd of March. Faculty opponent was professor Fredrik Frejd from Uppsala University.
[14 Oct 2015] We are happy to announce that an MTA has been signed with Morphotek, Exton, PA USA, that will make farletuzumab available for preclinical work-up of its potential to be used as an alphatherapy vector. Farletuzumab is an optimized anti-folate receptor alpha (FOLR1) mAb generated by Morphotek with their morphogenics technology, it is the humanized version of the murine LK26. The folate receptor alpha is overexpressed in ovarian cancer but almost absent in normal tissues making it a much suitable vector for radioimmunotherapy. Interestingly, this is the same antigen that we where aiming at in the mid-late 1990ies using a different antibody. Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.